Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

Jürgen Behr,Petra Neuser,Antje Prasse,Michael Kreuter,Klaus Rabe,Carmen Schade-Brittinger,Jasmin Wagner,Andreas Günther

DOI: https://doi.org/10.1186/s12890-017-0462-y

IF: 3.1

2017-09-06

BMC Pulmonary Medicine

Abstract:BackgroundPirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive fibrotic lung diseases, in which conventional anti-inflammatory therapy is not sufficiently effective and antifibrotic therapies may offer a novel treatment option.Methods/DesignWe designed a study protocol for inclusion of patients with progressive fibrotic lung disease despite conventional anti-inflammatory therapy (EudraCT 2014–000861-32). The study population comprises patients with collagen-vascular disease-associated lung fibrosis (CVD-LF), fibrotic non-specific interstitial pneumonia (fNSIP), chronic hypersensitivity pneumonitis (cHP), and asbestos-related lung fibrosis (ALF). Disease progression needs to be proven by slope calculation of at least three Forced Vital Capacity (FVC) values obtained within 6–24 months prior to inclusion, documenting an annualized decline in percent predicted FVC of 5% (absolute) or more despite appropriate conventional therapy. Absolute change in percent predicted FVC from baseline - analyzed using a rank analysis of covariance (ANCOVA) model - will serve as efficacy-related primary study endpoint.DiscussionThere is an urgent unmet clinical need for effective therapies for patients with a progressive fibrotic lung disease other than IPF. The current study protocol is unique with respect to selecting patients with different disease entities of lung fibrosis which have, however, essential pathophysiological characteristics in common. Moreover, by selecting patients with evidence of disease progression despite conventional therapy, the protocol ensures that a cohort of interstitial lung disease (ILD) patients with a high unmet medical need is targeted and it may allow a sufficiently high event rate for evaluation of treatment responses.Trial registrationDRKS00009822 (registration date: January 13th 2016).

respiratory system

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the efficacy and safety of oral pirfenidone in the treatment of progressive, non - idiopathic pulmonary fibrosis (non - IPF lung fibrosis). Specifically, the study focuses on the following diseases:

1. **Collagen - vascular disease - associated lung fibrosis (CVD - LF)**
2. **Fibrotic non - specific interstitial pneumonia (fNSIP)**
3. **Chronic hypersensitivity pneumonitis (cHP)**
4. **Asbestos - related lung fibrosis (ALF)**

These diseases are characterized by continued progression despite the use of traditional anti - inflammatory treatments. Therefore, the main purpose of the study is to evaluate whether pirfenidone can slow down the decline in lung function and improve exercise capacity in these patients, similar to its effect in patients with idiopathic pulmonary fibrosis (IPF).

### Research Background
- **Pirfenidone** is a drug that has been approved by the European Union for the treatment of mild - to - moderate idiopathic pulmonary fibrosis (IPF) and has a good risk - benefit ratio.
- **Other progressive fibrotic lung diseases**, such as CVD - LF, fNSIP, cHP, and ALF, have poor results with traditional anti - inflammatory treatments and require new treatment options.
- **Unmet clinical needs**: Patients with these diseases are in urgent need of effective treatment methods because their conditions progress rapidly and have a poor prognosis.

### Research Design
- **Randomized controlled trial**: This is a multi - center, randomized, double - blind, placebo - controlled parallel - group phase II clinical trial.
- **Study population**: Inclusion criteria include patients diagnosed with one of the above four types of pulmonary fibrosis, and who have proven a more than 5% annual decline in lung function through at least three lung function tests in the past 6 - 24 months.
- **Primary endpoint**: The absolute change in the predicted percentage of forced vital capacity (FVC) from baseline to week 48, analyzed using an analysis of covariance (ANCOVA) model.

### Secondary Endpoints
- **Time to disease worsening**: Defined as the time to clinical worsening, death related to pulmonary fibrosis, lung transplantation, or respiratory hospitalization.
- **Progression - free survival**: Defined as the time to the first occurrence of any of the following: a ≥10% decrease in the predicted percentage of FVC, a ≥15% decrease in the predicted percentage of hemoglobin - corrected carbon monoxide diffusing capacity (DLCO), or patient death.
- **Categorical assessment of relative change in FVC**.
- **Changes in the St. George's Respiratory Questionnaire (SGRQ) and the European Quality of Life - 5 Dimensions Questionnaire (EQ - 5D)**.
- **Changes in hemoglobin - corrected carbon monoxide diffusing capacity (DLCO)/carbon monoxide transfer capacity (TLCO)**.
- **Changes in the lowest pulse oxygen saturation (SpO2) during the 6 - minute walk test (6MWT)**.
- **Changes in the 6 - minute walk distance**.
- **Safety assessment**, including overall mortality.

### Research Significance
This study aims to fill the current gap in the treatment of non - idiopathic pulmonary fibrosis and provide potential effective treatment options for patients with these diseases. By selecting patients whose conditions progress despite receiving traditional treatment, the study ensures that it targets a cohort of patients with interstitial lung diseases (ILD) with high medical needs and may allow a high enough event rate to evaluate treatment responses.